Virpax Pharmaceuticals, Inc.

As of March 21, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, despite mixed signals from the MACD, KST, OBV, and RSI across different time frames.

Virpax Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $0.33 million. Key metrics include a debt-to-equity ratio of 1.51 and a return on equity of 1,206.72%.

As of Jun 18, Virpax Pharmaceuticals, Inc. has a market capitalization of 0.33 million, with net sales of 0.00 million and a net profit of -12.07 million over the last four quarters. The company reported shareholder's funds of -0.91 million and total assets of 1.56 million as of Dec 24.